TP53 and pancreatic intraductal papillary-mucinous neoplasm: By using a novel next-generation sequencing method, PDAC and IPMN cases could be distinguished even at low levels (0.1–1%) of TP53 and/or SMAD4 mutations in duodenal fluid, with 32.4% sensitivity and 100% specificity [53].